医药行业周报：艾伯维Epcoritamab在华申报上市

Investment Rating - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine industries, while the biopharmaceutical and other medical sectors are rated as neutral [1][7]. Core Insights - The pharmaceutical sector experienced a slight decline of -0.20% on November 6, 2024, outperforming the CSI 300 index by 0.30 percentage points, ranking 25th among 31 sub-industries in the Shenwan classification [3]. - Notable performances within the pharmaceutical sub-industries include offline pharmacies (+1.56%), medical research outsourcing (+0.57%), and hospitals (+0.54%), while medical equipment (-1.25%), other biological products (-0.66%), and medical consumables (-0.65%) lagged behind [3]. - AbbVie’s Epcoritamab has received acceptance for its new drug application in China, which is a CD3/CD20 bispecific antibody previously approved by the FDA for treating diffuse large B-cell lymphoma and follicular lymphoma [4]. Summary by Sections Market Performance - As of November 6, 2024, the pharmaceutical sector's performance was -0.20%, with a relative outperformance of 0.30 percentage points compared to the CSI 300 index [3]. Industry News - AbbVie’s Epcoritamab has been accepted for market application in China, indicating potential growth opportunities in the biopharmaceutical sector [4]. - Several companies, including Xinhua Pharmaceutical and Weishinkang, have received approvals for their respective products, indicating ongoing regulatory progress and potential market expansion [4]. Company News - Xinhua Pharmaceutical received approval for its calcium gluconate injection, while Weishinkang's subsidiary received approval for a compound electrolyte injection, both passing the consistency evaluation for generic drugs [4]. - Yipinhong's subsidiary has been approved to conduct clinical trials for a quadrivalent influenza recombinant protein vaccine, showcasing innovation in vaccine development [4].